Tetraspanin CD82 drives Acute Myeloid Leukemia chemoresistance by modulating Protein Kinase C alpha and β1 integrin activation

A principal challenge in treating acute myeloid leukemia (AML) is chemotherapy refractory disease. As such, there remains a critical need to identify key regulators of chemotherapy resistance in AML. In this study, we demonstrate that the membrane scaffold, CD82, contributes to the chemoresistant ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Floren, Muskan, Cruz, Sebastian Restrepo, Termini, Christina M., Marjon, Kristopher D., Lidke, Keith A., Gillette, Jennifer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210072/
https://www.ncbi.nlm.nih.gov/pubmed/32203165
http://dx.doi.org/10.1038/s41388-020-1261-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210072/
https://www.ncbi.nlm.nih.gov/pubmed/32203165
http://dx.doi.org/10.1038/s41388-020-1261-0

Ejemplares similares